Drug
Abp 938
Abp 938: highest development phase Phase 3, developed by Amgen. 1 trial record tracked on RxWires.
- Highest phase
- Phase 3
- Developer
- Amgen
Trials
| Drug | Phase | Indication |
|---|---|---|
| ABP 938 8 mg NCT07614776 | Phase 3 | Neovascular Age-related Macular Degeneration |
Latest
No recent events.
Follow Abp 938 on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.